Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels In Diabetes Animal Study
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience Corp. reports positive findings from its diabetes animal study DIAB-A22-1, showing that DehydraTECH-CBD reduced blood glucose levels by 19.9% and improved kidney function. However, the dementia study DEM-A22-1 produced inconclusive results, and the epilepsy study EPIL-A21-1 demonstrated DehydraTECH-CBD's effectiveness at lower doses compared to Epidiolex®.
June 16, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexaria's DehydraTECH-CBD demonstrated positive results in diabetes animal study, potentially opening new market opportunities for the company.
The positive results from the diabetes animal study indicate that DehydraTECH-CBD has the potential to be an effective treatment for diabetes-related conditions. This could open up new market opportunities for Lexaria, potentially increasing demand for their product and positively impacting their stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Positive results from Lexaria's diabetes animal study may lead to increased demand for DehydraTECH-CBD, potentially impacting the stock price of LEXXW.
The positive findings from the diabetes animal study suggest that DehydraTECH-CBD could be an effective treatment for diabetes-related conditions. This may lead to increased demand for the product, which could positively impact the stock price of LEXXW.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100